-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Octreotide LA in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Octreotide LA in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Octreotide LA in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – VMT-a-NET in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VMT-a-NET in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VMT-a-NET in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) Drug Details: VMT-a-NET is...
-
Product Insights
Minbu-GEP Solar Park
Minbu-GEP Solar Park is a solar PV project located in Magway, Myanmar. The project is owned by Green Earth Power (Thailand) Co Ltd and is developed by Green Earth Power (Thailand) Co Ltd; WElink Energy UK Ltd. The project is currently partially active. Empower your strategies with our Minbu-GEP Solar Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lutetium Lu 177 Dotatate in Neuroendocrine Tumors
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lutetium Lu 177 Dotatate in Neuroendocrine Tumors report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lutetium Lu 177 Dotatate in Neuroendocrine Tumors Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lutetium Lu 177 Dotatate in Pheochromocytoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lutetium Lu 177 Dotatate in Pheochromocytoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lutetium Lu 177 Dotatate in Pheochromocytoma Drug Details: Lutetium...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lutetium Lu 177 Dotatate in Neuroblastoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lutetium Lu 177 Dotatate in Neuroblastoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lutetium Lu 177 Dotatate in Neuroblastoma Drug Details: Lutetium...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PT-217 in Neuroendocrine Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PT-217 in Neuroendocrine Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PT-217 in Neuroendocrine Carcinoma Drug Details: PT-217 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PT-217 in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PT-217 in Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PT-217 in Prostate Cancer Drug Details: PT-217 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PT-217 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PT-217 in Small-Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PT-217 in Small-Cell Lung Cancer Drug Details: PT-217 is under development...